Select therapeutic use:
Indications for EDURANT:
In combination with other antiretroviral agents for HIV-1 infection in antiretroviral treatment-naïve patients with HIV-1 RNA ≤100,000 copies/mL at start of therapy.
Adults and Children:
<12yrs: not recommended. Take with a meal. ≥12yrs (≥35kg): 25mg once daily. Concomitant rifabutin: 50mg once daily; decrease to 25mg once daily when rifabutin is stopped.
Concomitant carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, dexamethasone (more than a single dose), St. John's wort.
Prolongation of QTc interval with supratherapeutic doses. Promptly evaluate if depressive symptoms occur. Monitor liver enzymes prior to initiation and during therapy in patients with underlying hepatitis B or C, or marked elevations in transaminases; consider monitoring LFTs in patients without pre-existing hepatic dysfunction or other risks. Discontinue immediately if severe skin or hypersensitivity reactions develop. Severe renal impairment or ESRD: monitor. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant NNRTIs (eg, delavirdine): not recommended. Caution when concomitant drugs with a known risk for torsades de pointes. Antagonized by CYP3A inducers (see Contraindications). May be potentiated by CYP3A inhibitors (eg, azole antifungals [monitor for breakthrough fungal infections], clarithromycin, erythromycin, telithromycin [consider azithromycin use]). Concomitant methadone; monitor. Separate antacids (by at least 2hrs before or at least 4hrs after) and H2-receptor antagonists (by at least 12hrs before or 4hrs after rilpivirine); drugs that increase gastric pH may result in decreased plasma concentrations.
Non-nucleoside reverse transcriptase inhibitor.
Depressive disorders, insomnia, headache, rash; hepatotoxicity, fat redistribution, immune reconstitution syndrome (monitor).
Hepatic (CYP3A4); 99.7% protein bound.
Fecal (primarily), renal.